Infectious Diseases and Immunity

Program

Professor Nigel McMillan

The Program

Biobanking Now in

Queensland.Prof Nigel McMillan

Director Dr Shirley Wee

Biobank ManagerGold Coast Biobank

Menzies Health Institute QueenslandGriffith University

• 12 grants totaling $8.6m• Gabrielle McCallum, Anne Chang, Robyn Marsh, Keith Grimwood, Yuejen Zhao, Kim Hare,

Peter Morris, Catherine Byrnes, Dennis Bonney, Mark Chatfield “Preventing recurrent respiratory-related hospitalisations in young Indigenous children through regular azithromycin: a multi- centre randomised controlled trial” NHMRC Project Grant $2.78m

• Anne Chang, Phil Robinson, Lucy Morgan, Keith Grimwood, Emma Duncan, Mark Chatfeild, Yuejen Zhao, Paul Leo, Andre Schultz, and Gabrielle McCallum. “Improving outcomes of children and young adults with primary ciliary dyskinesia: a multi-centre, double-blind, double-dummy, 2x2 factorial, randomised controlled trial (RCT)” MRFF, $2,375m

• Stafford Fox Medical Research Foundation Professorial Fellowships to Professor Sonya Marshall-Gradisnik and Professor Donald Staines. Value $1,954,000.00

• Cripps AW*, Cox AJ*, Smith P, Besseling Van der Vart I, Cromme C, West NP. A specific probiotic intervention to improve QoL in allergic rhinitis (PIQAR-study): a randomised, double-blind, placebo-controlled trial. 2019 – 2022. $687,950

• International Consortium: Impaired ion channel function in the pathomechanism and pharmacological treatment of Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). Jan 2019-Jan 2021 Value $355,181 Chief Investigators: Sonya Marshall-Gradisnik, Donald Staines, Katsuhiko Muraki (Aichi-Gakiun University, Japan), Daniel Peterson (Sierra Internal Medicine, Nevada, USA), Helene Cabanas.

Grant Success

• Bronchiectasis in children: diagnosis and treatment. Chang AB, Bush A, Grimwood K. Lancet. 2018 Sep 8;392(10150):866-879. doi: 10.1016/S0140-6736(18)31554-X. Review.

• Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Goyal V, Grimwood K, Byrnes CA, Morris PS, Masters IB, Ware RS, McCallum GB, Binks MJ, Marchant JM, van Asperen P, O'Grady KF, Champion A, Buntain HM, Petsky H, Torzillo PJ, Chang AB. Lancet. 2018 Oct 6;392(10154):1197-1206. doi: 10.1016/S0140-6736(18)31723-9.

• Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers. Shaikh MH, Idris A, Johnson NW, Fallaha S, Clarke DTW, Martin D, Morgan IM, Gabrielli B, McMillan NAJ. Oral Oncol. 2018 Nov;86:105-112. doi: 10.1016/j.oraloncology.2018.09.006

• Variation in hemolysin A expression between uropathogenic Escherichia coli isolates determines NLRP3-dependent vs. -independent macrophage cell death and host colonization. Murthy AMV, Sullivan MJ, Nhu NTK, Lo AW, Phan MD, Peters KM, Boucher D, Schroder K, Beatson SA, Ulett GC, Schembri MA, Sweet MJ. FASEB J. 2019 Mar 14:fj201802100R. doi: 10.1096/fj.201802100R.

• Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study.Słomko J, Newton JL, Kujawski S, Tafil-Klawe M, Klawe J, Staines D, Marshall-Gradisnik S, Zalewski P. BMJ Open. 2019 Mar 7;9(3):e023955. doi: 10.1136/bmjopen-2018-023955.

Paper Highlights

• Personalised therapy for head and neck cancer at GCH• MRFF pitch around genomics and gene medicines• Infection Symposium 2019 • BioBank Grand opening and one day conference• Summer School of Immunohistochemistry

Initiatives